In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Arrowhead Pharmaceuticals Inc.

www.arrowheadpharma.com

Latest From Arrowhead Pharmaceuticals Inc.

Coronavirus Update: Fujifilm Drug Shows Promise, Arrowhead Halts Trial Screening, Novartis Unveils COVID-19 Measures

Flu drug produces encouraging results in Chinese trials, while Novartis CEO Vas Narasimhan shows his public health background with package of measures.

International Coronavirus COVID-19

Stockwatch: Is Alnylam’s Rare Disease Business Model Sustainable?

Alnylam’s fourth-quarter and full-year 2019 earnings announcement was only one of eight announcements made by the company since early February. With the fundamental basis of its orphan drug business model still unvalidated by a profit, perhaps the more recent announcements are meant to distract investors’ attention with different metrics.

Platform Technologies Rare Diseases

Novartis’s Inclisiran Unscathed As Arrowhead Falls Short

Arrowhead’s drug has failed to match inclisiran’s performance, but its RNAi platform has other promising candidates.

Companies Research & Development

In Vivo's Rough Guide On The State Of RNAi

The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. In Vivo reviews the leading drug developers in this space.

Business Strategies Companies
See All

Company Information

  • Industry
  • Biotechnology
    • Antisense, Oligonucleotides
    • Gene Therapy, Cell Therapy
    • Large Molecule
    • Nanotechnology, Chips, etc.
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
      • Site Specific
  • Therapeutic Areas
  • Cancer
  • Cardiovascular
  • Hepatic (Liver)
  • Infectious & Viral Diseases
  • Metabolic Disorders
  • Alias(es)
  • Arrowhead Research Corp.
  • InterActive Group Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Arrowhead Pharmaceuticals Inc.
  • Senior Management
  • Christopher Anzalone, PhD, Pres. & CEO
    Ken Myszkowski, CFO
    James Hassard, Chief Commercial Officer
    Bruce Given, MD, COO
    Javier San Martin, MD, CMO
    Curt Bradshaw, PhD, CSO
  • Contact Info
  • Arrowhead Pharmaceuticals Inc.
    Phone: (626) 304-3400
    177 East Colorado Blvd.
    Ste. 700
    Pasadena, CA 91105
    USA
UsernamePublicRestriction

Register